Oxidative stress and inflammation in hepatic diseases: Therapeutic possibilities of N-acetylcysteine

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 30269-30308

  de Andrade, Kívia Queiroz ^a   Moura, Fabiana Andréa ^a,b   dos Santos, John Marques ^b   de Araújo, Orlando Roberto Pimentel ^b   Santos, Juliana Célia de Farias ^b   Goulart, Marília Oliveira Fonseca ^b  

^a Pós Graduação em Ciências da Saúde PPGCS   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

Author keywords

Anti inflammatory; Antioxidant; Biomarkers; Hepatic injury; Liver; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; CATALASE; GAMMA INTERFERON; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID PEROXIDE; LIPOPOLYSACCHARIDE; LIPOXYGENASE; MALONALDEHYDE; MYELOPEROXIDASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; XANTHINE OXIDASE; BIOLOGICAL MARKER;

ALCOHOL LIVER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER INJURY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SYSTEMATIC REVIEW; VIRUS HEPATITIS; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ACETYLCYSTEINE; ANIMALS; BIOMARKERS; HUMANS; INFLAMMATION; LIVER DISEASES; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 84951002164     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226225     Document Type: Review

References (257)

1. Chatterjee, R.; Mitra, A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int. Immunopharmacol. 2015, 24, 335-345. [CrossRef] [PubMed].
2. Invernizzi, P. Liver auto-immunology: The paradox of autoimmunity in a tolerogenic organ. J. Autoimmun. 2013, 46, 1-6. [CrossRef] [PubMed].
3. Raschzok, N.; Sallmon, H.; Pratschke, J.; Sauer, I.M. MicroRNAs in liver tissue engineering-New promises for failing organs. Adv. Drug Deliv. Rev. 2015, 88, 67-77. [CrossRef] [PubMed].
4. Leung, C.C.H.; Young, K.K. Clinical aspects of hepatic disease. Anaesth. Intensive Care Med. 2015, 16, 11-13. [CrossRef].
5. Mehal,W.Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 637-644. [CrossRef] [PubMed].
6. Chen, P.J.; Huang, C.; Meng, X.M.; Li, J. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis. Biochimie 2015, 116, 61-69. [CrossRef] [PubMed].
7. Duval, F.; Moreno-Cuevas, J.E.; Gonzalez-Garza, M.T.; Rodriguez-Montalvo, C.; Cruz-Vega, D.E. Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chin. Med. 2014, 9, 27. [CrossRef] [PubMed].
8. Diesen, D.L.; Kuo, P.C. Nitric oxide and redox regulation in the liver: Part II. Redox biology in pathologic hepatocytes and implications for intervention. J. Surg. Res. 2011, 167, 96-112. [CrossRef] [PubMed].
9. Santos, J.C.; Valentim, I.B.; de Araujo, O.R.; Ataide Tda, R.; Goulart, M.O. Development of nonalcoholic hepatopathy: Contributions of oxidative stress and advanced glycation end products. Int. J. Mol. Sci. 2013, 14, 19846-19866. [CrossRef] [PubMed].
10. Mormone, E.; George, J.; Nieto, N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem. Biol. Interact. 2011, 193, 225-231. [CrossRef] [PubMed].
11. Musacco-Sebio, R.; Saporito-Magrina, C.; Semprine, J.; Torti, H.; Ferrarotti, N.; Castro-Parodi, M.; Damiano, A.; Boveris, A.; Repetto, M.G. Rat liver antioxidant response to iron and copper overloads. J. Inorg. Biochem. 2014, 137, 94-100. [CrossRef] [PubMed].
12. Pisoschi, A.M.; Pop, A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur. J. Med. Chem. 2015, 97, 55-74. [CrossRef] [PubMed].
13. Chen, Y.; Johansson, E.; Yang, Y.; Miller, M.L.; Shen, D.; Orlicky, D.J.; Shertzer, H.G.; Vasiliou, V.; Nebert, D.W.; Dalton, T.P. Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. J. Hepatol. 2010, 53, 1085-1094. [CrossRef] [PubMed].
14. Chen, Y.; Dong, H.; Thompson, D.C.; Shertzer, H.G.; Nebert, D.W.; Vasiliou, V. Glutathione defense mechanism in liver injury: Insights from animal models. Food Chem. Toxicol. 2013, 60, 38-44. [CrossRef] [PubMed].
15. Okanoue, T.; Mitsuyoshi, H. Non-alcoholic steatohepatitis. 3. Oxidative stress and NASH. Nihon Naika Gakkai Zasshi 2006, 95, 51-56. [CrossRef] [PubMed].
16. Ribeiro, G.; Roehrs, M.; Bairros, A.; Moro, A.; Charao, M.; Araujo, F.; Valentini, J.; Arbo, M.; Brucker, N.; Moresco, R.; et al. N-acetylcysteine on oxidative damage in diabetic rats. Drug Chem. Toxicol. 2011, 34, 467-474. [CrossRef] [PubMed].
17. Kerksick, C.;Willoughby, D. The Antioxidant Role of Glutathione and N-acetylcysteine Supplements and Exercise-Induced Oxidative Stress. J. Int. Soc. Sports Nutr. 2005, 9, 38-44. [CrossRef] [PubMed].
18. Moura, F.A.; de Andrade, K.Q.; Dos Santos, J.C.; Araujo, O.R.; Goulart, M.O. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol. 2015, 6, 617-639. [CrossRef] [PubMed].
19. Li, J.; Zhang, S.; Wu, Y.; Guo, W.; Zhang, Y.; Zhai, W. Protective effects of N-acetylcysteine on the liver of brain-dead Ba-Ma mini pig. Transplant. Proc. 2010, 42, 195-199. [CrossRef] [PubMed].
20. Moore, S.M.; Kremer, M.; Sanderlin, E.J.; Wheeler, M.D.; Hines, I.N. Emerging Roles for Lipids in the Hepatic Innate Immune Response. Hum. Nutr. Food. Sci. 2013, 1, 1-9.
21. Videla, L.A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quiñones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A.; et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. 2004, 106, 261-268. [CrossRef] [PubMed].
22. D'Autreaux, B.; Toledano, M.B. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell. Biol. 2007, 8, 813-824. [CrossRef] [PubMed].
23. Mittler, R.; Vanderauwera, S.; Suzuki, N.; Miller, G.; Tognetti, V.B.; Vandepoele, K.; Gollery, M.; Shulaev, V.; van Breusegem, F. ROS signaling: The new wave? Trends Plant Sci. 2011, 16, 300-309. [CrossRef] [PubMed].
24. Tell, G.; Vascotto, C.; Tiribelli, C. Alterations in the redox state and liver damage: Hints from the EASL Basic School of Hepatology. J. Hepatol. 2013, 58, 365-374. [CrossRef] [PubMed].
25. Center, S.A. Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders. Vet. Clin. N. Am. Small Anim. Pract. 2004, 34, 67-172. [CrossRef].
26. Ho, E.; Karimi Galougahi, K.; Liu, C.C.; Bhindi, R.; Figtree, G.A. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol. 2013, 1, 483-491. [CrossRef] [PubMed].
27. Liochev, S.I.; Fridovich, I. The relative importance of HO. and ONOO-in mediating the toxicity of O. Free Radic. Biol. Med. 1999, 26, 777-778. [PubMed].
28. Rolo, A.P.; Teodoro, J.S.; Palmeira, C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52, 59-69. [CrossRef] [PubMed].
29. Silva, D.C.; Cerchiaro, G.; Honório, K.M. Relações patofisiológicas entre estresse oxidativo e arteriosclerose. Quim. Nova 2011, 34, 300-305. [CrossRef].
30. Giavarotti, K.A.S. Estudo do estresse oxidativo hepático induzido por lindano em um modelo de hipertireoidismo experimental. Ph.D. Thesis, Universidade de São Paulo, São Paulo, Brazil, 9 February 2001.
31. Possamai, F.P. Estudo do Estresse Oxidativo em Órgãos de RatosWistar Adultos Induzidos à Intoxicação por Malation. Master's Thesis, Universidade do Extremo Sul Catarinense, Santa Catarina, Brazil, 2005.
32. Marí, M.; Colell, A.; Morales, A.; von Montfort, C.; Garcia-Ruiz, C.; Fernández-Checa, J.C. Redox control of liver function in health and disease. Antioxid. Redox Signal. 2010, 12, 1295-1331. [CrossRef] [PubMed].
33. Serviddio, G.; Bellanti, F.; Vendemiale, G. Free radical biology for medicine: Learning from nonalcoholic fatty liver disease. Free Radic. Biol. Med. 2013, 65, 952-968. [CrossRef] [PubMed].
34. Vasconcelos, S.M.L.; Goulart, M.O.F.; Moura, J.B.F.; Manfredini, V.; Benfato, M.S.; Kubota, L.T. Espécies reativas de oxigênio e de nitrogênio, antioxidantes e marcadores de dano oxidativo em sangue humano: Principais métodos analíticos para sua determinação. Quím. Nova 2007, 30, 1323-1338. [CrossRef].
35. Edwards, L.; Wanless, I.R. Mechanisms of liver involvement in systemic disease. Best Pract. Res. Clin. Gastroenterol. 2013, 27, 471-483. [CrossRef] [PubMed].
36. Santos, J.C.; de Araujo, O.R.; Valentim, I.B.; de Andrade, K.Q.; Moura, F.A.; Smaniotto, S.; dos Santos, J.M.; Gasparotto, J.; Gelain, D.P.; Goulart, M.O. Choline and Cystine deficient diets in animal models with hepatocellular injury: Evaluation of oxidative stress and expression of RAGE, TNF-α, and IL-1β. Oxid. Med. Cell. Longev. 2015, 2015, 121925. [CrossRef] [PubMed].
37. Zhou, W.C.; Zhang, Q.B.; Qiao, L. Pathogenesis of liver cirrhosis. World J. Gastroenterol. 2014, 20, 7312-7324. [CrossRef] [PubMed].
38. Baffy, G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J. Hepatol. 2009, 51, 212-223. [CrossRef] [PubMed].
39. Nakamoto, N.; Kanai, T. Role of toll-like receptors in immune activation and tolerance in the liver. Front. Immunol. 2014, 5, 221. [CrossRef] [PubMed].
40. Samuni, Y.; Goldstein, S.; Dean, O.M.; Berk, M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta 2013, 1830, 4117-4129. [CrossRef] [PubMed].
41. Haddad, J.J. Oxygen homeostas is, thiol equilibrium and redox regulation of signalling transcription factors in the alveolar epithelium. Cell Signal. 2002, 14, 799-810. [CrossRef].
42. Bhogal, R.H.; Curbishley, S.M.; Weston, C.J.; Adams, D.H.; Afford, S.C. Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation. Liver Transpl. 2010, 16, 1303-1313. [CrossRef] [PubMed].
43. Czaja, A.J. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J. Gastroenterol. 2014, 20, 2515-2532. [CrossRef] [PubMed].
44. Compare, D.; Coccoli, P.; Rocco, A.; Nardone, O.M.; de Maria, S.; Carteni, M.; Nardone, G. Gut-Liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 471-476. [CrossRef] [PubMed].
45. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 2010, 49, 1603-1616. [CrossRef] [PubMed].
46. Chen, L.; Li, J.; Zhang, J.; Dai, C.; Liu, X.; Wang, J.; Gao, Z.; Guo, H.; Wang, R.; Lu, S.; et al. S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J. Hepatol. 2015, 62, 156-164. [CrossRef] [PubMed].
47. Giraudi, P.J.; Becerra, V.J.; Marin, V.; Chavez-Tapia, N.C.; Tiribelli, C.; Rosso, N. The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Exp. Mol. Pathol. 2015, 98, 85-92. [CrossRef] [PubMed].
48. Pelz, S.; Stock, P.; Bruckner, S.; Christ, B. A methionine-choline-deficient diet elicits NASH in the immunodeficient mouse featuring a model for hepatic cell transplantation. Exp. Cell. Res. 2012, 318, 276-287. [CrossRef] [PubMed].
49. Cohen-Naftaly, M.; Friedman, S.L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther. Adv. Gastroenterol. 2011, 4, 391-417. [CrossRef] [PubMed].
50. Atkuri, K.R.; Mantovani, J.J.; Herzenberg, L.A.; Herzenberg, L.A. N-acetylcysteine-A safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 2007, 7, 355-359. [CrossRef] [PubMed].
51. Tirouvanziam, R.; Conrad, C.K.; Bottiglieri, T.; Herzenberg, L.A.; Moss, R.B.; Herzenberg, L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci. USA 2006, 103, 4628-4633. [CrossRef] [PubMed].
52. Rushworth, G.F.; Megson, I.L. Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol. Ther. 2014, 141, 150-159. [CrossRef] [PubMed].
53. Arranz, L.; Fernandez, C.; Rodriguez, A.; Ribera, J.M.; de la Fuente, M. The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women. Free Radic. Biol. Med. 2008, 45, 1252-1262. [CrossRef] [PubMed].
54. Baumgardner, J.N.; Shankar, K.; Hennings, L.; Albano, E.; Badger, T.M.; Ronis, M.J.J. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J. Nutr. 2008, 138, 1872-1879. [PubMed].
55. Garaiová, I.; Muchová, J.; Šustrová, M.; Blažícěk3, P.; Sivonôvá, M.; Kvasnicǩa, P.; Pueschel, S.; Duracǩová, Z. The relationship b etween antioxidant systems and some markers of oxidative stress in persons with down syndrome. Biol. Bratisl. 2004, 59, 787-794.
56. Atkinson, M.C. The Use of N-acetylcysteine in Intensive Care. Lit. Rev. 2002, 4, 21-27.
57. Aitio, M.L. N-acetylcysteine-Passe-partout or much ado about nothing? Br. J. Clin. Pharmacol. 2005, 61, 5-15. [CrossRef] [PubMed].
58. Noszál, B.; Visky, D.; Kraszni, M. Population, acid-base, and redox properties of N-acetylcysteine conformers. J. Med. Chem. 2000, 43, 2176-2182. [CrossRef] [PubMed].
59. Sadowska, A.M.; Manuel, Y.K.B.; de Backer, W.A. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review. Pulm Pharmacol. Ther. 2007, 20, 9-22. [CrossRef] [PubMed].
60. Akca, T.; Canbaz, H.; Tataroglu, C.; Caglikulekci, M.; Tamer, L.; Colak, T.; Kanik, A.; Bilgin, O.; Aydin, S. The effect of N-acetylcysteine on pulmonary lipid peroxidation and tissue damage. J. Surg. Res. 2005, 129, 38-45. [CrossRef] [PubMed].
61. Kasperczyk, S.; Dobrakowski, M.; Kasperczyk, A.; Machnik, G.; Birkner, E. Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers. Environ. Toxicol. Pharmacol. 2014, 37, 638-647. [CrossRef] [PubMed].
62. Oliveira, V.A.; Oliveira, C.S.; Mesquita, M.; Pedroso, T.F.; Costa, L.M.; Fiuza Tda, L.; Pereira, M.E. Zinc and N-acetylcysteine modify mercury distribution and promote increase in hepatic metallothionein levels. J. Trace Elem. Med. Biol. 2015, 32, 183-188. [CrossRef] [PubMed].
63. Jones, C.M.; Lawrence, A.; Wardman, P.; Burkitt, M.J. Kinetics of superoxide scavenging by glutathione: An evaluation of its role in the removal of mitochondrial superoxide. Biochem Soc. Trans. 2003, 31, 1337-1339. [CrossRef] [PubMed].
64. Sarnstrand, B.; Jansson, A.H.; Matuseviciene, G.; Scheynius, A.; Pierrou, S.; Bergstrand, H. N,N1-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-Is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J. Pharmacol. Exp. Ther. 1999, 288, 1174-1184. [PubMed].
65. Dodd, S.; Dean, O.; Copolov, D.L.; Malhi, G.S.; Berk, M. N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility. Expert Opin. Biol. Ther. 2008, 8, 1955-1962. [CrossRef] [PubMed].
66. Zhang, S.; Chai, F.Y.; Yan, H.; Guo, Y.; Harding, J.J. Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. Mol. Vis. 2008, 14, 862-870. [PubMed].
67. Griffith, O.W.; Meister, A. Glutathione: Interorgan translocation, turnover, and metabolism. Proc. Natl. Acad. Sci. USA 1979, 76, 5606-5610. [CrossRef] [PubMed].
68. Lasram, M.M.; Dhouib, I.B.; Annabi, A.; El Fazaa, S.; Gharbi, N. A review on the possible molecular mechanism of action of N-acetylcysteine against insulin resistance and type-2 diabetes development. Clin. Biochem. 2015. [CrossRef] [PubMed].
69. Bonanomi, L.; Gazzaniga, A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur. J. Respir. Dis. Suppl. 1980, 111, 45-51. [PubMed].
70. Sheffner, A.L.; Medler, E.M.; Bailey, K.R.; Gallo, D.G.; Mueller, A.J.; Sarett, H.P. Metabolic studies with acetylcysteine. Biochem. Pharmacol. 1966, 15, 1523-1535. [CrossRef].
71. Borgström, L.; Kågedal, B.; Paulsen, O. Pharmacokinetics of N-acetylcysteine in man. Eur. J. Clin. Pharmacol. 1986, 31, 217-222. [CrossRef] [PubMed].
72. Rosa, S.C.; Zaretsky, M.D.; Dubs, J.G.; Roederer, M.; Anderson, M.; Green, A.; Mitra, D.; Watanabe, N.; Nakamura, H.; Tjioe, I.; et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Investig. 2000, 30, 915-929. [CrossRef].
73. Cetinkaya, A.; Bulbuloglu, E.; Kurutas, E.B.; Ciralik, H.; Kantarceken, B.; Buyukbese, M.A. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J. Exp. Med. 2005, 206, 131-139. [CrossRef] [PubMed].
74. Guijarro, L.G.; Mate, J.; Gisbert, J.P.; Perez-Calle, J.L.; Marin-Jimenez, I.; Arriaza, E.; Olleros, T.; Delgado, M.; Castillejo, M.S.; Prieto-Merino, D.; et al. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. World J. Gastroenterol. 2008, 14, 2851-2857. [CrossRef] [PubMed].
75. Baker,W.L.; Anglade, M.W.; Baker, E.L.; White, C.M.; Kluger, J.; Coleman, C.I. Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: A meta-analysis. Eur. J. Cardiothorac. Surg. 2009, 35, 521-527. [CrossRef] [PubMed].
76. Dröge, W.; Eck, H.P.; Mihm, S. HIV-induced cysteine deficiency and T-cell dysfunction-A rationale for treatment with N-acetylcysteine. Immunol. Today 1992, 13, 211-214. [CrossRef].
77. Berk, M.; Malhi, G.S.; Gray, L.J.; Dean, O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 2013, 34, 167-177. [CrossRef] [PubMed].
78. Çağlıkülekci, M.; Pata, C.; Apa, D.D.; Dirlik, M.; Tamer, L.; Yaylak, F.; Kanik, A.; Aydin, S. The effect of N-acetylcysteine (NAC) on liver and renal tissue inducible nitric oxide synthase (iNOS) and tissue lipid peroxidation in obstructive jaundice stimulated by lipopolysaccharide (LPS). Pharmacol. Res. 2004, 49, 227-238. [CrossRef] [PubMed].
79. Hayakawa, M.; Miyashita, H.; Sakamoto, I.; Kitagawa, M.; Tanaka, H.; Yasuda, H.; Karin, M.; Kikugawa, K. Evidence that reactive oxygen species do not mediate NF-kB activation. EMBO J. 2003, 22, 3356-3366. [CrossRef] [PubMed].
80. Hou, Y.; Wang, L.; Yi, D.; Ding, B.; Yang, Z.; Li, J.; Chen, X.; Qiu, Y.; Wu, G. N-acetylcysteine reduces inflammation in the small intestine by regulating redox, EGF and TLR4 signaling. Amino Acids 2013, 45, 513-522. [CrossRef] [PubMed].
81. Park, E.; Yu, K.H.; Kim do, K.; Kim, S.; Sapkota, K.; Kim, S.J.; Kim, C.S.; Chun, H.S. Protective effects of N-acetylcysteine against monosodium glutamate-induced astrocytic cell death. Food Chem. Toxicol. 2014, 67, 1-9. [CrossRef] [PubMed].
82. Parasassi, T.; Brunelli, R.; Bracci-Laudiero, L.; Greco, G.; Gustafsson, A.C.; Krasnowska, E.K.; Lundeberg, J.; Lundeberg, T.; Pittaluga, E.; Romano, M.C.; et al. Differentiation of normal and cancer cells induced by sulfhydryl reduction: Biochemical and molecular mechanisms. Cell Death Differ. 2005, 12, 1285-1296. [CrossRef] [PubMed].
83. Lin, K.T.; Xue, J.Y.; Sun, F.F.; Wong, P.Y. Reactive oxygen species participate in peroxynitrite-induced apoptosis in HL-60 cells. Biochem. Biophys. Res. Commun. 1997, 230, 115-119. [CrossRef] [PubMed].
84. Zaragoza, A.; Díez-Fernándeza, C.; Alvarezb, A.M.; Andrésa, D.; Cascales, M. Effect of N-acetylcysteine and deferoxamine on endogenous antioxidant defense system gene expression in a rat hepatocyte model of cocaine cytotoxicity. Biochim. Biophys. Acta 2000, 1496, 183-195. [CrossRef].
85. Mahapatra, S.K.; Bhattacharjee, S.; Chakraborty, S.P.; Majumdar, S.; Roy, S. Alteration of immune functions and Th1/Th2 cytokine balance in nicotine-induced murine macrophages: Immunomodulatory role of eugenol and N-acetylcysteine. Int. Immunopharmacol. 2011, 11, 485-495. [CrossRef] [PubMed].
86. Hafiz, A.M.A.E.; Wakeel, L.M.E.; Hady, H.M.E.; Mourad, A.E.R. High dose N-acetyl cysteine improves inflammatory response and outcome in patients with COPD exacerbations. Egypt. J. Chest Dis. Tuberc. 2013, 62, 51-57. [CrossRef].
87. Zafarullah, M.; Li, W.Q.; Sylvester, J.; Ahmad, M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003, 60, 6-20. [CrossRef] [PubMed].
88. Afford, S.C.; Humphreys, E.H.; Reid, D.T.; Russell, C.L.; Banz, V.M.; Oo, Y.; Vo, T.; Jenne, C.; Adams, D.H.; Eksteen, B. Vascular cell adhesion molecule 1 expression by biliary epithelium promotes persistence of inflammation by inhibiting effector T-cell apoptosis. Hepatology 2014, 59, 1932-1943. [CrossRef] [PubMed].
89. Csontos, C.; Rezman, B.; Foldi, V.; Bogar, L.; Drenkovics, L.; Roth, E.; Weber, G.; Lantos, J. Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn. Burns 2012, 38, 428-437. [CrossRef] [PubMed].
90. Paterson, R.L.; Galley, H.F.; Webster, N.R. The effect of N-acetylcysteine on nuclear factor-kB activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit. Care Med. 2003, 31, 2574-2578. [CrossRef] [PubMed].
91. Kim, H.J.; Chang, E.J.; Kim, H.M.; Lee, S.B.; Kim, H.D.; Su Kim, G.; Kim, H.H. Antioxidant α-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kB ligand and tumor necrosis factor-α. Free Radic. Biol. Med. 2006, 40, 1483-1493. [CrossRef] [PubMed].
92. Pajonk, F.; Riess, K.; Sommer, A.; McBride, W.H. N-acetyl-L-cysteine inhibits 26S proteasome function: Implications for effects on NF-kB activation. Free Radic. Biol. Med. 2002, 32, 536-543. [CrossRef].
93. Oka, S.; Kamata, H.; Kamata, K.; Yagisawa, H.; Hirata, H. N-acetylcysteine suppresses TNF-induced NF-kB activation through inhibition of IkB kinases. FEBS Lett. 2000, 472, 196-202. [CrossRef].
94. Ingaramo, P.I.; Ronco, M.T.; Frances, D.E.; Monti, J.A.; Pisani, G.B.; Ceballos, M.P.; Galleano, M.; Carrillo, M.C.; Carnovale, C.E. Tumor necrosis factor α pathways develops liver apoptosis in type 1 diabetes mellitus. Mol. Immunol. 2011, 48, 1397-1407. [CrossRef] [PubMed].
95. Ronco, M.T.; Alvarez Mde, L.; Monti, J.A.; Carrillo, M.C.; Pisani, G.B.; Lugano, M.C.; Carnovale, C.E. Role of nitric oxide increase on induced programmed cell death during early stages of rat liver regeneration. Biochim. Biophys. Acta 2004, 1690, 70-76. [CrossRef] [PubMed].
96. Rabkin, S.W.; Klassen, S.S. Nitric oxide differentially regulates the gene expression of caspase genes but not some autophagic genes. Nitric Oxide 2007, 16, 339-347. [CrossRef] [PubMed].
97. Mohd Hanafiah, K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57, 1333-1342. [CrossRef] [PubMed].
98. Pisani, P.; Parkin, D.M.; Munoz, N.; Ferlay, J. Cancer and infection: Estimates of the attributable fraction in 1990 Cancer Epidemiol. Biomark. Prev. 1997, 6, 387-400.
99. Poli, G. Pathogenesis of liver fibrosis: Role of oxidative stress. Mol. Asp. Med. 2000, 21, 49-98. [CrossRef].
100. Farias, M.S.; Budni, P.; Ribeiro, C.M.; Parisotto, E.B.; Santos, C.E.; Dias, J.F.; Dalmarco, E.M.; Frode, T.S.; Pedrosa, R.C.;Wilhelm Filho, D. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Gastroenterol. Hepatol. 2012, 35, 386-394. [CrossRef] [PubMed].
101. Ko, W.S.; Guo, C.H.; Yeh, M.S.; Lin, L.Y.; Hsu, G.S.; Chen, P.C.; Luo, M.C.; Lin, C.Y. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J. Gastroenterol. 2005, 11, 4697-4702. [PubMed].
102. Miyanishi, K.; Hoki, T.; Tanaka, S.; Kato, J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. World J. Hepatol. 2015, 7, 593-599. [CrossRef] [PubMed].
103. Gong, G.; Waris, G.; Tanveer, R.; Siddiqui, A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kB. Proc. Natl. Acad. Sci. USA 2001, 98, 9599-9604. [CrossRef] [PubMed].
104. Tardif, K.D.; Waris, G.; Siddiqui, A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 2005, 13, 159-163. [CrossRef] [PubMed].
105. Moura, F.A.; de Andrade, K.Q.; dos Santos, J.C.; Goulart, M.F.O. Lipoic acid: Its antioxidant and anti-inflammatory role and clinical applications. Curr. Top. Med. Chem. 2015, 15, 458-483. [CrossRef] [PubMed].
106. Shedlofsky, S.I. Role of iron in the natural history and clinical course of hepatitis C disease. Hepatogastroenterology 1998, 45, 349-355. [PubMed].
107. Metwally, M.A.; Zein, C.O.; Zein, N.N. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am. J. Gastroenterol. 2004, 99, 286-291. [CrossRef] [PubMed].
108. Rojas, C.; Matos, B.; Santiago, N.; Reymunde, A.; Matta, J.L. Hepatitis C patients in puerto rico have an altered iron balance. Biol. Trace Elem. Res. 2001, 84, 239-245. [CrossRef].
109. Shan, Y.; Lambrecht, R.W.; Bonkovsky, H.L. Association of hepatitis C virus infection with serum iron status: Analysis of data from the third National Health and Nutrition Examination Survey. Clin. Infect. Dis. 2005, 40, 834-841. [CrossRef] [PubMed].
110. Bulatova, I.A.; Tret'iakova, I.I.; Shchekotov, V.V.; Shchekotova, A.P.; Ulitina, P.V.; Krivtsov, A.V.; Nenasheva, O.I. Catalase gene rs1001179 polymorphism and oxidative stress in patients with chronic hepatitis C and ulcerative colitis. Ter. Arkh. 2015, 87, 49-53. [PubMed].
111. Bitetto, D.; Bortolotti, N.; Falleti, E.; Vescovo, S.; Fabris, C.; Fattovich, G.; Cussigh, A.; Cmet, S.; Fornasiere, E.; Ceriani, E.; et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 2013, 57, 925-933. [CrossRef] [PubMed].
112. Masri, O.A.; Chalhoub, J.M.; Sharara, A.I. Role of vitamins in gastrointestinal diseases. World J. Gastroenterol. 2015, 21, 5191-5209. [CrossRef] [PubMed].
113. Khadem Ansari, M.H.; Omrani, M.D.; Kheradmand, F. Oxidative stress response in patients infected by diverse hepatitis C virus genotypes. Hepat. Mon. 2015, 15, e22069. [CrossRef] [PubMed].
114. Gabr, S.A.; Alghadir, A.H. Prediction of fibrosis in hepatitis C patients: Assessment using hydroxyproline and oxidative stress biomarkers. Virusdisease 2014, 25, 91-100. [CrossRef] [PubMed].
115. Bunchorntavakul, C.; Wootthananont, T.; Atsawarungruangkit, A. Effects of vitamin E on chronic hepatitis C genotype 3: A randomized, double-blind, placebo-controlled study. J. Med. Assoc. Thail. 2014, 97, 31-40.
116. Vonghia, L.; Michielsen, P.; Francque, S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int. J. Mol. Sci. 2013, 14, 19867-19890. [CrossRef] [PubMed].
117. Trépo, C.; Chan, H.L.Y.; Lok, A. Hepatitis B virus infection. Lancet 2014, 384, 2053-2063. [CrossRef].
118. McMahon, B.J. Natural history of chronic hepatitis B. Clin. Liver Dis. 2010, 14, 381-396. [CrossRef] [PubMed].
119. Seiva, F.R.F.; Amauchi, J.F.; Rocha, K.K.R.; Souza, G.A.; Ebaid, G.X.; Burneiko, R.M.; Novelli, E.L. Effects of N-acetylcysteine on alcohol abstinence and alcohol-induced adverse effects in rats. Alcohol 2009, 43, 127-135. [CrossRef] [PubMed].
120. Tong, A.;Wu, L.; Lin, Q.; Lau, Q.C.; Zhao, X.; Li, J.; Chen, P.; Chen, L.; Tang, H.; Huang, C.;Wei, Y.Q. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 2008, 8, 2012-2023. [CrossRef] [PubMed].
121. Hajjou, M.; Norel, R.; Carver, R.; Marion, P.; Cullen, J.; Rogler, L.E.; Rogler, C.E. cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J. Med. Virol. 2005, 77, 57-65. [CrossRef] [PubMed].
122. Li, H.; Zhu,W.; Zhang, L.; Lei, H.;Wu, X.; Guo, L.; Chen, X.; Wang, Y.; Tang, H. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Sci. Rep. 2015, 5, 8421. [CrossRef] [PubMed].
123. Kim, Y.S.; Seo, H.W.; Jung, G. Reactive oxygen species promote heat shock protein 90-mediated HBV capsid assembly. Biochem. Biophys. Res. Commun. 2015, 457, 328-333. [CrossRef] [PubMed].
124. Acar, A.; Gorenek, L.; Aydin, A.; Eyigun, C.P.; Eken, A.; Sayal, A.; Pahsa, A. Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-α plus lamivudine combination therapy on oxidative stress. Mikrobiyol. Bulteni 2009, 43, 411-423.
125. Tasdelen Fisgin, N.; Aydin, B.K.; Sarikaya, H.; Tanyel, E.; Esen, S.; Sunbul, M.; Leblebicioglu, H. Oxidative stress and antioxidant defense in patients with chronic hepatitis B. Clin. Lab. 2012, 58, 273-280. [PubMed].
126. Dikici, I.; Mehmetoglu, I.; Dikici, N.; Bitirgen, M.; Kurban, S. Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-α treatment. Clin. Biochem. 2005, 38, 1141-1144. [CrossRef] [PubMed].
127. Duygu, F.; Karsen, H.; Aksoy, N.; Taskin, A. Relationship of oxidative stress in hepatitis B infection activity with HBV DNA and fibrosis. Ann. Lab. Med. 2012, 32, 113-118. [CrossRef] [PubMed].
128. Takaki, A.; Yamamoto, K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J. Hepatol. 2015, 7, 968-979. [CrossRef] [PubMed].
129. O'Shea, R.S.; Dasarathy, S.; McCullough, A.J.; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010, 51, 307-328. [PubMed].
130. Rehm, J.; Mathers, C.; Popova, S.; Thavorncharoensap, M.; Teerawattananon, Y.; Patra, J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009, 373, 2223-2233. [CrossRef].
131. MacSween, R.N.; Burt, A.D. Histologic spectrum of alcoholic liver disease. Semin. Liver Dis. 1986, 6, 221-232. [CrossRef] [PubMed].
132. Setshedi, M.;Wands, J.R.; Monte, S.M. Acetaldehyde adducts in alcoholic liver disease. Oxid. Med. Cell Longev. 2010, 3, 178-185. [CrossRef] [PubMed].
133. Forrest, E.; Reed, E. Alcohol and the liver. Medicine 2011, 39, 532-535. [CrossRef].
134. Qu, B.G.; Wang, H.; Jia, Y.G.; Su, J.L.; Wang, Z.D.; Wang, Y.F.; Han, X.H.; Liu, Y.X.; Pan, J.D.; Ren, G.Y. Changes in tumor necrosis factor-α, heat shock protein 70, malondialdehyde, and superoxide dismutase in patients with different severities of alcoholic fatty liver disease: A prospective observational study. Medicine 2015, 94, e643. [CrossRef] [PubMed].
135. Grasselli, E.; Compalati, A.D.; Voci, A.; Vecchione, G.; Ragazzoni, M.; Gallo, G.; Borro, P.; Sumberaz, A.; Testino, G.; Vergani, L. Altered oxidative stress/antioxidant status in blood of alcoholic subjects is associated with alcoholic liver disease. Drug Alcohol Depend. 2014, 143, 112-119. [CrossRef] [PubMed].
136. Parthasarathy, R.; Kattimani, S.; Sridhar, M.G. Oxidative stress during alcohol withdrawal and its relationship with withdrawal severity. Indian J. Psychol. Med. 2015, 37, 175-180. [PubMed].
137. Pivetta, L.A.; Pereira, R.P.; Farinon, M.; de Bem, A.F.; Perottoni, J.; Soares, J.C.; Duarte, M.M.; Zeni, G.; Rocha, J.B.; Farina, M. Ethanol inhibits α-aminolevulinate dehydratase and glutathione peroxidase activities in mice liver: Protective effects of ebselen and N-acetylcysteine. Environ. Toxicol. Pharmacol. 2006, 21, 338-343. [CrossRef] [PubMed].
138. Caro, A.A.; Bell, M.; Ejiofor, S.; Zurcher, G.; Petersen, D.R.; Ronis, M.J. N-acetylcysteine inhibits the up-regulation of mitochondrial biogenesis genes in livers from rats fed ethanol chronically. Alcohol. Clin. Exp. Res. 2014, 38, 2896-2906. [CrossRef] [PubMed].
139. Wang, A.L.; Wang, J.P.; Wang, H.; Chen, Y.H.; Zhao, L.; Wang, L.S.; Wei, W.; Xu, D.X. A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2006, 34, 199-206. [CrossRef] [PubMed].
140. Thong-Ngam, D.; Samuhasaneeto, S.; Kulaputana, O.; Klaikeaw, N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J. Gastroenterol. 2007, 13, 5127-5132. [CrossRef] [PubMed].
141. Samuhasaneeto, S.; Thong-Ngam, D.; Kulaputana, O.; Patumraj, S.; Klaikeaw, N. Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis. J. Med. Assoc. Thail. 2007, 90, 788-797.
142. Demiroren, K.; Dogan, Y.; Kocamaz, H.; Ozercan, I.H.; Ilhan, S.; Ustundag, B.; Bahcecioglu, I.H. Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clin. Res. Hepatol. Gastroenterol. 2014, 38, 63-72. [CrossRef] [PubMed].
143. Vendemiale, G.; Grattagliano, I.; Caruso, M.L.; Serviddio, G.; Valentini, A.M.; Pirrelli, M.; Altomare, E. Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: Effect of N-acetylcysteine and interferon-α. Toxicol. Appl. Pharmacol. 2001, 175, 130-139. [CrossRef] [PubMed].
144. Tsuyuki, S.; Yamauchi, A.; Nakamura, H.; Nakamura, Y.; Kinoshita, K.; Gomi, T.; Kawai, Y.; Hirose, T.; Furuke, K.; Ikai, I.; et al. N-acetylcysteine improves cytotoxic activity of cirrhotic rat liver-associated mononuclear cells. Int. Immunol. 1998, 10, 1501-1508. [CrossRef] [PubMed].
145. Lei, S.; Liu, Y.; Liu, H.; Yu, H.; Wang, H.; Xia, Z. Effects of N-acetylcysteine on nicotinamide dinucleotide phosphate oxidase activation and antioxidant status in heart, lung, liver and kidney in streptozotocin-induced diabetic rats. Yonsei Med. J. 2012, 53, 294-303.
146. Diniz, Y.S.; Rocha, K.K.; Souza, G.A.; Galhardi, C.M.; Ebaid, G.M.; Rodrigues, H.G.; Novelli Filho, J.L.; Cicogna, A.C.; Novelli, E.L. Effects of N-acetylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur. J. Pharmacol. 2006, 543, 151-157. [CrossRef] [PubMed].
147. Sun, Y.; Pu, L.Y.; Lu, L.; Wang, X.H.; Zhang, F.; Rao, J.H. N-acetylcysteine attenuates reactive-oxygen-species-mediated endoplasmic reticulum stress during liver ischemia-reperfusion injury. World J. Gastroenterol. 2014, 20, 15289-15298. [CrossRef] [PubMed].
148. Fernandez, V.; Vargas, R.; Castillo, V.; Cadiz, N.; Bastias, D.; Roman, S.; Tapia, G.; Videla, L.A. Reestablishment of ischemia-reperfusion liver injury by N-acetylcysteine administration prior to a preconditioning iron protocol. Sci. World J. 2013, 2013, 1-9. [CrossRef] [PubMed].
149. Demir, S.; Inal-Erden, M. Pentoxifylline and N-acetylcysteine in hepatic ischemia/reperfusion injury. Clin. Chim. Acta 1998, 275, 127-135. [CrossRef].
150. Sener, G.; Tosun, O.; Sehirli, A.Ö.; Kaçmaz, A.; Arbak, S.; Ersoy, Y.; Ayanoğlu-Dülger, G. Melatonin and N-acetylcysteine have beneficial effects during hepatic ischemia and reperfusion. Life Sci. 2003, 72, 2707-2718. [CrossRef].
151. Wang, C.; Chen, K.; Xia, Y.; Dai, W.; Wang, F.; Shen, M.; Cheng, P.; Wang, J.; Lu, J.; Zhang, Y.; et al. N-acetylcysteine attenuates ischemia-reperfusion-induced apoptosis and autophagy in mouse liver via regulation of the ROS/JNK/Bcl-2 pathway. PLoS ONE 2014, 9, e108855. [CrossRef] [PubMed].
152. Lin, H.; Liu, X.B.; Yu, J.J.; Hua, F.; Hu, Z.W. Antioxidant N-acetylcysteine attenuates hepatocarcinogenesis by inhibiting ROS/ER stress in TLR2 deficient mouse. PLoS ONE 2013, 8, e74130. [CrossRef] [PubMed].
153. Tian, Y.; Kuo, C.F.; Sir, D.; Wang, L.; Govindarajan, S.; Petrovic, L.M.; Ou, J.H. Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. Cell. Death Differ. 2015, 22, 1025-1034. [CrossRef] [PubMed].
154. Galicia-Moreno, M.; Favari, L.; Muriel, P. Antifibrotic and antioxidant effects of N-acetylcysteine in an experimental cholestatic model. Eur. J. Gastroenterol. Hepatol. 2012, 24, 179-185. [CrossRef] [PubMed].
155. Ritter, C.; Reinke, A.; Andrades, M.; Martins, M.R.; Rocha, J.; Menna-Barreto, S.; Quevedo, J.; Moreira, J.C.F.; Dal-Pizzol, F. Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats. Crit. Care Med. 2004, 32, 2079-2083. [CrossRef] [PubMed].
156. Bemeur, C.; Vaquero, J.; Desjardins, P.; Butterworth, R.F. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: Antioxidant and anti-inflammatory mechanisms. Metab. Brain Dis. 2010, 25, 241-249. [CrossRef] [PubMed].
157. Seif el-Din, S.H.; Al-Hroob, A.M.; Ebeid, F.A. Schistosoma mansoni: N-acetylcysteine downregulates oxidative stress and enhances the antischistosomal activity of artemether in mice. Exp. Parasitol. 2011, 128, 230-235. [CrossRef] [PubMed].
158. Hsu, B.G.; Lee, R.P.; Yang, F.L.; Harn, H.J.; Chen, H.I. Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci. 2006, 79, 2010-2016. [CrossRef] [PubMed].
159. Ronis, M.J.; Butura, A.; Sampey, B.P.; Shankar, K.; Prior, R.L.; Korourian, S.; Albano, E.; Ingelman-Sundberg, M.; Petersen, D.R.; Badger, T.M. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic. Biol. Med. 2005, 39, 619-630. [CrossRef] [PubMed].
160. Setshedi, M.; Longato, L.; Petersen, D.R.; Ronis, M.; Chen, W.C.; Wands, J.R.; de la Monte, S.M. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol. Clin. Exp. Res. 2011, 35, 2139-2151. [CrossRef] [PubMed].
161. Bajt, M.L.; Knight, T.R.; Lemasters, J.J.; Jaeschke, H. Acetaminophen-induced oxidant stress and cell injury in cultured mouse hepatocytes: Protection by N-acetyl cysteine. Toxicol. Sci. 2004, 80, 343-349. [CrossRef] [PubMed].
162. Taslipinar, M.Y.; Aydin, I.; Kaldirim, U.; Aydin, F.N.; Agilli, M.; Eyi, Y.E.; Tuncer, S.K.; Altayli, E.; Ucar, F.; Macit, E.; et al. Hyperbaric oxygen treatment and N-acetylcysteine ameliorate acetaminophen-induced liver injury in a rat model. Hum. Exp. Toxicol. 2013, 32, 1107-1116. [CrossRef] [PubMed].
163. Acharya, M.; Lau-Cam, C.A. Comparison of the protective actions of N-acetylcysteine, hypotaurine and taurine against acetaminophen-induced hepatotoxicity in the rat. J. Biomed. Sci. 2010, 17 (Suppl. S1), 1-11. [CrossRef] [PubMed].
164. Terneus, M.V.; Brown, J.M.; Carpenter, A.B.; Valentovic, M.A. Comparison of S-adenosyl-L-methionine (SAMe) and N-acetylcysteine (NAC) protective effects on hepatic damage when administered after acetaminophen overdose. Toxicology 2008, 244, 25-34. [CrossRef] [PubMed].
165. Rafeiro, E.; Barr, S.G.; Harrison, J.J.; Racz,W.J. Effects of N-acetylcysteine and dithiothreitol on glutathione and protein thiol replenishment during acetaminophen-induced toxicity in isolated mouse hepatocytes. Toxicology 1994, 93, 209-224. [CrossRef].
166. Manov, I.; Hirsh, M.; Iancu, T.C. Acetaminophen hepatotoxicity and mechanisms of its protection by N-acetylcysteine: A study of Hep3B cells. Exp. Toxicol. Pathol. 2002, 53, 489-500. [CrossRef] [PubMed].
167. Al-Mustafa, Z.H.; Al-Ali, A.K.; Qaw, F.S.; Abdul-Cader, Z. Cimetidine enhances the hepatoprotective action of N-acetylcysteine in mice treated with toxic doses of paracetamol. Toxicology 1997, 121, 223-228. [CrossRef].
168. Tobwala, S.; Khayyat, A.; Fan, W.; Ercal, N. Comparative evaluation of N-acetylcysteine and N-acetylcysteineamide in acetaminophen-induced hepatotoxicity in human hepatoma HepaRG cells. Exp. Biol. Med. 2015, 240, 261-272. [CrossRef] [PubMed].
169. Rana, S.V.; Attri, S.; Vaiphei, K.; Pal, R.; Attri, A.; Singh, K. Role of N-acetylcysteine in rifampicin-induced hepatic injury of young rats. World J. Gastroenterol. 2006, 12, 287-291. [PubMed].
170. Raza, M.; Ahmad, M.; Gado, A.; Al-Shabanah, O.A. A comparison of hepatoprotective activities of aminoguanidine and N-acetylcysteine in rat against the toxic damage induced by azathioprine. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2003, 134, 451-456. [CrossRef].
171. Carvalho, M.; Remiao, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Carvalho, F.; Bastos, M.L. The toxicity of N-methyl-α-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004, 200, 193-203. [PubMed].
172. Kaya, H.; Koc, A.; Sogut, S.; Duru, M.; Yilmaz, H.R.; Uz, E.; Durgut, R. The protective effect of N-acetylcysteine against cyclosporine A-induced hepatotoxicity in rats. J. Appl. Toxicol. 2008, 28, 15-20. [CrossRef] [PubMed].
173. Abdoli, N.; Azarmi, Y.; Eghbal, M.A. Protective Effects of N-acetylcysteine against the Statins Cytotoxicity in Freshly Isolated Rat Hepatocytes. Adv. Pharm. Bull. 2014, 4, 249-254. [PubMed].
174. Akbulut, S.; Elbe, H.; Eris, C.; Dogan, Z.; Toprak, G.; Otan, E.; Erdemli, E.; Turkoz, Y. Cytoprotective effects of amifostine, ascorbic acid and N-acetylcysteine against methotrexate-induced hepatotoxicity in rats. World J. Gastroenterol. 2014, 20, 10158-10165. [CrossRef] [PubMed].
175. Maheswari, E.; Saraswathy, G.R.; Santhranii, T. Hepatoprotective and antioxidant activity of N-acetyl cysteine in carbamazepine-administered rats. Indian J. Pharmacol. 2014, 46, 211-215. [CrossRef] [PubMed].
176. Lasram, M.M.; Lamine, A.J.; Dhouib, I.B.; Bouzid, K.; Annabi, A.; Belhadjhmida, N.; Ahmed, M.B.; El Fazaa, S.; Abdelmoula, J.; Gharbi, N. Antioxidant and anti-inflammatory effects of N-acetylcysteine against malathion-induced liver damages and immunotoxicity in rats. Life Sci. 2014, 107, 50-58. [CrossRef] [PubMed].
177. Mostafalou, S.; Abdollahi, M.; Eghbal, M.A.; Saeedi Kouzehkonani, N. Protective effect of NAC against malathion-induced oxidative stress in freshly isolated rat hepatocytes. Adv. Pharm. Bull. 2012, 2, 79-88. [PubMed].
178. Ahmad, I.; Shukla, S.; Kumar, A.; Singh, B.K.; Kumar, V.; Chauhan, A.K.; Singh, D.; Pandey, H.P.; Singh, C. Biochemical and molecular mechanisms of N-acetyl cysteine and silymarin-mediated protection against maneb-and paraquat-induced hepatotoxicity in rats. Chem. Biol. Interact. 2013, 201, 9-18. [CrossRef] [PubMed].
179. Van Tonder, J.J.; Gulumian, M.; Cromarty, A.D.; Steenkamp, V. In vitro effect of N-acetylcysteine on hepatocyte injury caused by dichlorodiphenyltrichloroethane and its metabolites. Hum. Exp. Toxicol. 2014, 33, 41-53. [CrossRef] [PubMed].
180. Dhouib, I.E.-B.; Annabi, A.; Lasram, M.M.; Gharbi, N.; El-Fazaa, S. Anti-inflammatory Effects of N-acetylcysteine against Carbosulfan-induced Hepatic Impairment in Male Rats. Recent Adv. Biol. Med. 2015, 1, 29-40. [CrossRef].
181. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45, 1366-1374. [CrossRef] [PubMed].
182. Mansour, H.H.; Hafez, H.F.; Fahmy, N.M.; Hanafi, N. Protective effect of N-acetylcysteine against radiation induced DNA damage and hepatic toxicity in rats. Biochem. Pharmacol. 2008, 75, 773-780. [CrossRef] [PubMed].
183. Joshi, D.; Mittal, D.K.; Shukla, S.; Srivastav, A.K.; Srivastav, S.K. N-acetyl cysteine and selenium protects mercuric chloride-induced oxidative stress and antioxidant defense system in liver and kidney of rats: A histopathological approach. J. Trace Elem. Med. Biol. 2014, 28, 218-226. [CrossRef] [PubMed].
184. Kamalakkannan, N.; Rukkumani, R.; Aruna, K.; Varma, P.; Viswanathan, P.; Padmanabhan Menon, V. Protective effect of N-acetyl cysteine in carbon tetrachloride-induced hepatotoxicity in rats. Iran. J. Pharmacol. Ther. 2005, 4, 118-123.
185. Nissar, A.U.; Farrukh, M.R.; Kaiser, P.J.; Rafiq, R.A.; Afnan, Q.; Bhushan, S.; Adil, H.S.; Subhash, B.C.; Tasduq, S.A. Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in Wistar rat. Phytomedicine 2013, 20, 828-833. [CrossRef] [PubMed].
186. Cai, Z.; Lou, Q.;Wang, F.; Li, E.; Sun, J.; Fang, H.; Xi, J.; Ju, L. N-acetylcysteine protects against liver injure induced by carbon tetrachloride via activation of the Nrf2/HO-1 pathway. Int. J. Clin. Exp. Pathol. 2015, 8, 8655-8662. [PubMed].
187. Odewumi, C.O.; Badisa, V.L.; Le, U.T.; Latinwo, L.M.; Ikediobi, C.O.; Badisa, R.B.; Darling-Reed, S.F. Protective effects of N-acetylcysteine against cadmium-induced damage in cultured rat normal liver cells. Int. J. Mol. Med. 2011, 27, 243-248. [CrossRef] [PubMed].
188. Wang, J.; Zhu, H.; Liu, X.; Liu, Z. N-acetylcysteine protects against cadmium-induced oxidative stress in rat hepatocytes. J. Vet. Sci. 2014, 15, 485. [CrossRef] [PubMed].
189. Gonzalez-Rubio, S.; Linares, C.I.; Bello, R.I.; Gonzalez, R.; Ferrin, G.; Hidalgo, A.B.; Munoz-Gomariz, E.; Rodriguez, B.A.; Barrera, P.; Ranchal, I.; et al. Calcium-dependent nitric oxide production is involved in the cytoprotective properties of N-acetylcysteine in glycochenodeoxycholic acid-induced cell death in hepatocytes. Toxicol. Appl. Pharmacol. 2010, 242, 165-172. [CrossRef] [PubMed].
190. Skrzydlewska, E.; Farbiszewski, R. Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication. Drug Alcohol. Depend. 1999, 57, 61-67. [CrossRef].
191. Pawlowska-Goral, K.; Kurzeja, E.; Stec, M. N-acetylcysteine protects against fluoride-induced oxidative damage in primary rat hepatocytes. Toxicol. Vitro 2013, 27, 2279-2282. [CrossRef] [PubMed].
192. Sathish, P.; Paramasivan, V.; Palani, V.; Sivanesan, K. N-acetylcysteine attenuates dimethylnitrosamine induced oxidative stress in rats. Eur. J. Pharmacol. 2011, 654, 181-186. [CrossRef] [PubMed].
193. Modi, M.; Kaul, R.K.; Kannan, G.M.; Flora, S.J. Co-administration of zinc and N-acetylcysteine prevents arsenic-induced tissue oxidative stress in male rats. J. Trace Elem. Med. Biol. 2006, 20, 197-204. [CrossRef] [PubMed].
194. Brandao, R.; Nogueira, C.W. Inhibition of hepatic delta-aminolevulinate dehydratase activity induced by mercuric chloride is potentiated by N-acetylcysteine in vitro. Food Chem. Toxicol. 2011, 49, 305-308. [CrossRef] [PubMed].
195. Beyaz, S.G.; Yelken, B.; Kanbak, G. The effects of N-acetylcysteine on hepatic function during isoflurane anaesthesia for laparoscopic surgery patients. Indian J. Anaesth. 2011, 55, 567-572. [CrossRef] [PubMed].
196. Huang, H.; Yin, R.; Zhu, J.; Feng, X.; Wang, C.; Sheng, Y.; Dong, G.; Li, D.; Jing, H. Protective effects of melatonin and N-acetylcysteine on hepatic injury in a rat cardiopulmonary bypass model. J. Surg. Res. 2007, 142, 153-161. [CrossRef] [PubMed].
197. Altinoz, E.; Turkoz, Y.; Vardi, N. The protective effect of N-acetylcysteine against acrylamide toxicity in liver and small and large intestine tissues. Bratisl. Lek. Listy 2015, 116, 252-258. [CrossRef] [PubMed].
198. Williams, C.D.; Stengel, J.; Asike, M.I.; Torres, D.M.; Shaw, J.; Contreras, M.; Landt, C.L.; Harrison, S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011, 140, 124-131. [CrossRef] [PubMed].
199. Adams, L.A.; Lindor, K.D. Nonalcoholic fatty liver disease. Ann. Epidemiol. 2007, 17, 11. [CrossRef] [PubMed].
200. Vernon, G.; Baranova, A.; Younossi, Z.M. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34, 274-285. [CrossRef] [PubMed].
201. De Medeiros, I.C.; de Lima, J.G. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease?-A mechanistic hypothesis. Med. Hypotheses 2015, 85, 148-152. [CrossRef] [PubMed].
202. Day, C.P.; James, O.F. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998, 114, 842-845. [CrossRef].
203. Houstis, N.; Rosen, E.D.; Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440, 944-948. [CrossRef] [PubMed].
204. Al Rifai, M.; Silverman, M.G.; Nasir, K.; Budoff, M.J.; Blankstein, R.; Szklo, M.; Katz, R.; Blumenthal, R.S.; Blaha, M.J. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015, 239, 629-633. [CrossRef] [PubMed].
205. Ozenirler, S.; Erkan, G.; Konca Degertekin, C.; Ercin, U.; Cengiz, M.; Bilgihan, A.; Yilmaz, G.; Akyol, G. The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis. J. Dig. Dis. 2014, 15, 131-136. [CrossRef] [PubMed].
206. Sayre, L.M.; Lin, D.; Yuan, Q.; Zhu, X.; Tang, X. Protein adducts generated from products of lipid oxidation: Focus on HNE and one. Drug Metabol. Rev. 2006, 38, 651-675. [CrossRef] [PubMed].
207. Farhangi, M.A.; Alipour, B.; Jafarvand, E.; Khoshbaten, M. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: Effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch. Med. Res. 2014, 45, 589-595. [CrossRef] [PubMed].
208. Horoz, M.; Bolukbas, C.; Bolukbas, F.F.; Sabuncu, T.; Aslan, M.; Sarifakiogullari, S.; Gunaydin, N.; Erel, O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol. 2005, 5, 35. [CrossRef] [PubMed].
209. Koruk, M.; Taysi, S.; Savas, M.C.; Yilmaz, O.; Akcay, F.; Karakok, M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann. Clin. Lab. Sci. 2004, 34, 57-62. [PubMed].
210. Athyros, V.G.; Tziomalos, K.; Katsiki, N.; Doumas, M.; Karagiannis, A.; Mikhailidis, D.P. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J. Gastroenterol. 2015, 21, 6820-6834. [PubMed].
211. Linhart, K.B.; Glassen, K.; Peccerella, T.;Waldherr, R.; Linhart, H.; Bartsch, H.; Seitz, H.K. The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg. Nutr. 2015, 4, 117-123. [PubMed].
212. Dinkova-Kostova, A.T.; Holtzclaw,W.D.; Kensler, T.W. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 2005, 18, 1779-1791. [CrossRef] [PubMed].
213. Lei, S.; Liu, Y.; Liu, H.; Yu, H.; Wang, H.; Xia, Z. Effects of N-acetylcysteine on nicotinamide dinucleotide phosphate oxidase activation and antioxidant status in heart, lung, liver and kidney in streptozotocin-induced diabetic rats. Yonsei Med. J. 2012, 53, 294-303. [CrossRef] [PubMed].
214. Kim, J.Y.; Lee, S.H.; Song, E.H.; Park, Y.M.; Lim, J.Y.; Kim, D.J.; Choi, K.H.; Park, S.I.; Gao, B.; Kim,W.H. A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: Controlled by ATF3. Cell Signal. 2009, 21, 1758-1767. [CrossRef] [PubMed].
215. Trivedi, P.P.; Jena, G.B. Ulcerative colitis-induced hepatic damage in mice: Studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem. Biol. Interact. 2013, 201, 19-30. [CrossRef] [PubMed].
216. Jiang,W.;Wu, N.;Wang, X.; Chi, Y.; Zhang, Y.; Qiu, X.; Hu, Y.; Li, J.; Liu, Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci. Rep. 2015, 5, 8096. [CrossRef] [PubMed].
217. Trivedi, P.P.; Jena, G.B. Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: Studies on inflammation, oxidative stress, DNA damage and fibrosis. Food Chem. Toxicol. 2013, 59, 339-355. [CrossRef] [PubMed].
218. Cesaro, C.; Tiso, A.; del Prete, A.; Cariello, R.; Tuccillo, C.; Cotticelli, G.; del Vecchio Blanco, C.; Loguercio, C. Gut microbiota and probiotics in chronic liver diseases. Dig. Liver Dis. 2011, 43, 431-438. [CrossRef] [PubMed].
219. Henao-Mejia, J.; Elinav, E.; Thaiss, C.A.; Licona-Limon, P.; Flavell, R.A. Role of the intestinal microbiome in liver disease. J. Autoimmun. 2013, 46, 66-73. [CrossRef] [PubMed].
220. Koppe, S.W. Obesity and the liver: Nonalcoholic fatty liver disease. Transl. Res. 2014, 164, 312-322. [CrossRef] [PubMed].
221. Sourianarayanane, A.; Garg, G.; Smith, T.H.; Butt, M.I.; McCullough, A.J.; Shen, B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J. Crohns Colitis 2013, 7, e279-e285. [CrossRef] [PubMed].
222. Carter-Kent, C.; Zein, N.N.; Feldstein, A.E. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: Implications for treatment. Am. J. Gastroenterol. 2008, 103, 1036-1042. [CrossRef] [PubMed].
223. Chen, M.; Suzuki, A.; Borlak, J.; Andrade, R.J.; Lucena, M.I. Drug-induced liver injury: Interactions between drug properties and host factors. J. Hepatol. 2015, 63, 503-514. [CrossRef] [PubMed].
224. Au, J.S.; Pockros, P.J. Drug-induced liver injury from antiepileptic drugs. Clin. Liver Dis. 2013, 17, 687-697. [CrossRef] [PubMed].
225. Yuan, L.; Kaplowitz, N. Mechanisms of drug-induced liver injury. Clin. Liver Dis. 2013, 17, 507-518. [CrossRef] [PubMed].
226. Björnsson, E.S.; Bergmann, O.M.; Björnsson, H.K.; Kvaran, R.B.; Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144, 1419-1425. [CrossRef] [PubMed].
227. Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002, 36, 451-455. [CrossRef] [PubMed].
228. Amirana, S.; Babby, J. A Review of Drug-induced Liver Injury. J. Nurs. Pract. 2015, 11, 270-271. [CrossRef].
229. Tan, C.Y.; Saw, T.Y.; Fong, C.W.; Ho, H.K. Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injury. Redox Biol. 2015, 4, 308-320. [CrossRef] [PubMed].
230. Baveco, J.M.; Roos, A.M.D. Assessing the Impact of Pesticides on Lumbricid Populations: An Individual Based Modelling Approach. J. Appl. Ecol. 1996, 33, 1451-1468. [CrossRef].
231. Ojha, A.; Yaduvanshi, S.K.; Pant, S.C.; Lomash, V.; Srivastava, N. Evaluation of DNA damage and cytotoxicity induced by three commonly used organophosphate pesticides individually and in mixture, in rat tissues. Environ. Toxicol. 2013, 28, 543-552. [CrossRef] [PubMed].
232. Yamano, T.; Morita, S. Hepatotoxicity of trichlorfon and dichlorvos in isolated rat hepatocytes. Toxicology 1992, 76, 69-77. [CrossRef].
233. Numan, I.T.; Hassan, M.Q.; Stohs, S.J. Protective effects of antioxidants against endrin-induced lipid peroxidation, glutathione depletion, and lethality in rats. Arch. Environ. Contam. Toxicol. 1990, 19, 302-306. [CrossRef] [PubMed].
234. Hassan, M.Q.; Numan, I.T.; Al-Nasiri, N.; Stohs, S.J. Endrin-induced histopathological changes and lipid peroxidation in livers and kidneys of rats, mice, guinea pigs and hamsters. Toxicol. Pathol. 1991, 19, 108-114. [CrossRef] [PubMed].
235. Dalton, S.R.; Lee, S.M.; King, R.N.; Nanji, A.A.; Kharbanda, K.K.; Casey, C.A.; McVicker, B.L. Carbon tetrachloride-induced liver damage in asialoglycoprotein receptor-deficient mice. Biochem. Pharmacol. 2009, 77, 1283-1290. [CrossRef] [PubMed].
236. Muriel, P. Role of free radicals in liver diseases. Hepatol. Int. 2009, 3, 526-536. [CrossRef] [PubMed].
237. Domenicali, M.; Vendemiale, G.; Serviddio, G.; Grattagliano, I.; Pertosa, A.M.; Nardo, B.; Principe, A.; Viola, A.; Trevisani, F.; Altomare, E.; et al. Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. Dig. Liver Dis. 2005, 37, 689-697. [CrossRef] [PubMed].
238. Montalvo-Jave, E.E.; Escalante-Tattersfield, T.; Ortega-Salgado, J.A.; Pina, E.; Geller, D.A. Factors in the pathophysiology of the liver ischemia-reperfusion injury. J. Surg. Res. 2008, 147, 153-159. [CrossRef] [PubMed].
239. Serracino-Inglott, F.; Habib, N.A.; Mathie, R.T. Hepatic ischemia-reperfusion injury. Am. J. Surg. 2001, 181, 160-166. [CrossRef].
240. Fukuda, K.; Asoh, S.; Ishikawa, M.; Yamamoto, Y.; Ohsawa, I.; Ohta, S. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochem. Biophys. Res. Commun. 2007, 361, 670-674. [CrossRef] [PubMed].
241. Kireev, R.; Bitoun, S.; Cuesta, S.; Tejerina, A.; Ibarrola, C.; Moreno, E.; Vara, E.; Tresguerres, J.A. Melatonin treatment protects liver of Zucker rats after ischemia/reperfusion by diminishing oxidative stress and apoptosis. Eur. J. Pharmacol. 2013, 701, 185-193. [CrossRef] [PubMed].
242. Glantzounis, G.K.; Yang, W.; Koti, R.S.; Mikhailidis, D.P.; Seifalian, A.M.; Davidson, B.R. The role of thiols in liver ischemia-reperfusion injury. Curr. Pharm. Des. 2006, 12, 2891-2901. [CrossRef] [PubMed].
243. Jiang, L.; Wang, L.; Chen, L.; Cai, G.H.; Ren, Q.Y.; Chen, J.Z.; Shi, H.J.; Xie, Y.H. As2O3 induces apoptosis in human hepatocellular carcinoma HepG2 cells through a ROS-mediated mitochondrial pathway and activation of caspases. Int. J. Clin. Exp. Med. 2015, 8, 2190-2196. [PubMed].
244. Borro, P.; Leone, S.; Testino, G. Liver disease and hepatocellular carcinoma in alcoholics: The role of anticraving therapy. Curr. Drug Targets 2015, 16, 13.
245. Miura, K.; Taura, K.; Kodama, Y.; Schnabl, B.; Brenner, D.A. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008, 48, 1420-1429. [CrossRef] [PubMed].
246. Nishikawa, T.; Nakajima, T.; Katagishi, T.; Okada, Y.; Jo, M.; Kagawa, K.; Okanoue, T.; Itoh, Y.; Yoshikawa, T. Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation. Liver Int. 2009, 29, 846-856. [CrossRef] [PubMed].
247. Valavanidis, A.; Vlachogianni, T.; Fiotakis, C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health Part C Environ. Carcinog. Ecotoxicol. Rev. 2009, 27, 120-139. [CrossRef] [PubMed].
248. Roessner, A.; Kuester, D.; Malfertheiner, P.; Schneider-Stock, R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 2008, 204, 511-524. [CrossRef] [PubMed].
249. Yoo, J.; Hamilton, S.J.; Angel, D.; Fung, K.; Franklin, J.; Parnes, L.S.; Lewis, D.; Venkatesan, V.;Winquist, E. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: A pilot randomized study in head and neck cancer patients. Laryngoscope 2014, 124, E87-E94. [CrossRef] [PubMed].
250. Lin, P.C.; Lee, M.Y.; Wang, W.S.; Yen, C.C.; Chao, T.C.; Hsiao, L.T.; Yang, M.H.; Chen, P.M.; Lin, K.P.; Chiou, T.J. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: Preliminary data. Support. Care Cancer 2006, 14, 484-487. [CrossRef] [PubMed].
251. Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931-947. [CrossRef] [PubMed].
252. Turner, P.V.; Brabb, T.; Pekow, C.; Vasbinder, M.A. Administration of substances to laboratory animals: Routes of administration and factors to consider. J. Am. Assoc. Lab. Anim. Sci. 2011, 50, 600-613. [PubMed].
253. Lukas, G.; Brindle, S.D.; Greengard, P. The route of absorption of intraperitoneally administered compounds. J. Pharmacol. Exp. Ther. 1971, 178, 562-564. [PubMed].
254. Abu-Hijleh, M.F.; Habbal, O.A.; Moqattash, S.T. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J. Anat. 1995, 186 Pt 3, 453-467. [PubMed].
255. Schmitt, B.; Vicenzi, M.; Garrel, C.; Denis, F.M. Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study. Redox Biol. 2015, 6, 198-205. [CrossRef] [PubMed].
256. Kadiiska, M.B.; Peddada, S.; Herbert, R.A.; Basu, S.; Hensley, K.; Jones, D.P.; Hatch, G.E.; Mason, R.P. Biomarkers of oxidative stress study VI. Endogenous plasma antioxidants fail as useful biomarkers of endotoxin-induced oxidative stress. Free Radic. Biol. Med. 2015, 81, 100-106. [CrossRef] [PubMed].
257. Calder, P.C.; Ahluwalia, N.; Albers, R.; Bosco, N.; Bourdet-Sicard, R.; Haller, D.; Holgate, S.T.; Jonsson, L.S.; Latulippe, M.E.; Marcos, A.; et al. A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br. J. Nutr. 2013, 109 (Suppl. S1), S1-S34. [CrossRef] [PubMed].